Abstract: Background: Many factors are currently being identified as potential inductors of skin cancer in patients after a liver transplant, among them, immunosuppressive regimen. oBjective: To study the factors that influence the incidence of skin cancer in patients after liver transplant. Methods: We have carried out a retrospective and observational study with 170 transplanted patients who had undergone transplantation from 1997 to 2010. We have adjusted the multiple logistic regression model (saturated model) to the ensemble of collected data using skin cancer as dependent variable, indicated in anatomopathological analysis between 1997 and 2014. results: Incidence of skin cancer was 9.4%. Predictors were incidence of diabetes in the third year after the transplantation (p=0.047), not using tacrolimus in the first year after the transplantation (p=0.025) and actinic keratosis (p=0.003). study liMitations: An important limitation is that the interpretation of the results was based on information collected of patients undergoing transplantation at a single center. Future research, multicentric and involving larger and more diverse populations, are needed. conclusions: Factors found might contribute to Brazilian surveillance programs associated with decreased incidence of skin cancer.
INTRODUCTION
The performance of organ transplants is a very important achievement in the health system, being a safe and effective therapeutic alternative in the treatment of several diseases. 1 It is a fact that much of the progress in liver transplant is due to the development of immunosuppressive regimens. However, high doses of these drugs and their prolonged use imply toxicity. Thus, Medicine began to experience the increase of diseases in immunodeficient organisms, such as pharmacodermia, infections, photosensitivity, malignant and pre-malignant tumors, as well as transplantation typical diseases, such as graft-versus-host disease. 1 As is the case in the general population, carcinoma is the most common malignant tumor, as well as the greatest cause of morbidity among post-transplant patients. 2, 3 Incidence of skin cancer is increasing rapidly in several countries. However, there are estimates that worldwide, 45% of preventable carcinomas are cutaneous. 4 Overall, it is believed that 90% of non-melanoma skin cancers and 65% of melanomas can be attributed to sun exposure.
Non-melanoma skin cancer is more associated with cumulative solar action, while melanoma, with intense episodes of acute sun exposure, resulting in sunburn. 5 Non-melanoma skin cancer accounts for more than 90% of post-transplant skin cancers. In contrast to general population, transplant recipients develop squamous cell carcinoma (SCC) more often than basal cell carcinoma (BCC). 6, 7 Thus, SCC can occur 65 to 250 times more frequently in transplanted patients than in the general population, whereas BCC occurs 10 to 20 times more frequently. 8, 9 Lesions appear, on average, two to four years after transplantation and increase in frequency over time. This is particularly important because, in addition to SCC being more aggressive than BCC, it has a tendency to recur, particularly in immunocompromised patients. 10 Incidence of Non-melanoma skin cancer in liver, kidney and heart transplant recipients ranges from 1.5% to 22%, 2% to 24%, and from 6% to 34%, respectively, within five years of transplant, depending on geographic location and other factors. 10 Malignant cutaneous neoplasms are well-known complications after organ transplantation; however the risk factors associated with its development are still not well defined in post-liver transplant patients. SCCs were classified according to the invasion (in microinvasive, superficial and frankly invasive) and by the degree of differentiation (in well, moderately and poorly differentiated), which is based on four criteria, namely cytological atypia, mitotic activity, intercellular bridges and cornification, as described by Broders. 
METHODS

RESULTS
Of the 349 liver transplant recipients, 179 were excluded (155 with survival <3 years after transplantation and 24 with incomplete data or who used another drug in the immunosuppressive regimen rather than tacrolimus and cyclosporine). The study included 170 patients.
Sixteen (9.4%) patients in the study group (n=170) presented skin cancer after liver transplantation, according to anatomopathological analysis from 1997 to 2014. Seven patients had only one skin cancer and nine patients had more than one skin cancer, totaling 30 cutaneous neoplasias (Table 1) . Seven patients had previously selected actinic keratoses, with suspected epidermoid carcinoma.
Among the 30 skin cancers found, 22 were SCCs, and according to the degree of differentiation, one was poorly differentiated, six were well differentiated and 15 were moderately differentiated ( Figure 1 ). According to the degree of invasion, eight were frankly invasive, one was microinvasive and 13, were superficial.
All BCCs were nodular. Two patients developed CMM, one being Clark I and the other Clark IV (Table 1) . No specimen had, in the adjacent or underlying dermis, grade I elastosis; eight presented grade II elastosis; 11, grade III; and in the other 11 slides, it was not possible to evaluate the degree of elastosis.
There was a high prevalence of male patients (72.4%) and mean age of 47.5 years (standard deviation ± 11.2 years) at the time of transplantation.
Regarding race, 16/170 patients were brown, 1/170 was black and 153/170 were white.
Patients studied had a mean MELD score of 19.16 (standard deviation ± 6.3) and a mean BAR score of 6.9 (standard deviation ± 3.6).
C virus hepatitis was the cause for more frequent transplantation followed by alcoholic cirrhosis and hepatocellular carcinoma (Table 2 ).
In the first year after transplantation, the most commonly used immunosuppressant in the study population was tacrolimus, the drug of choice in 65.9% of patients. In the period between the first and third years, 13.5% of the patients received tacrolimus and cyclosporine at different periods, and 20.6% received only cyclosporine. 10, 12 In the studied population, incidence of skin cancer was 9.4% of the cases (n=16); of these, 87.5% (14/16) of the patients had non-melanoma skin cancer; 6.25% (1/16), malignant melanoma; and 6.25% (1/16), BCC concomitant with CMM.
Incidence of skin cancer found in the study population was within the range described in the literature for individuals treated with liver transplantation (1.5% to 22%). 10, 12 A study by Mithoefer et al. 2 in the USA, with 151 liver transplant recipients and a mean follow-up of four years, showed a cumulative incidence of non-melanoma skin cancer of 22% in all patients. However, a study conducted by Jonas et al., in Germany, with 458 patients, found a cumulative incidence of skin cancer of only 1.5% after a follow-up with duration similar to that of other authors. 13 Regarding solar elastosis, the majority had marked elastosis, showing the participation of photodamage as a cocarcinogen in post-transplantation cancers.
Clinical use of tacrolimus is increasing, and the drug is currently the based on more than 80% of liver transplants and 30% of kidney transplants. 3 In the first year after transplantation, this immunosuppressant was used in 65.9%
(n=112/170) of patients in this study.
Frezza et al. 14 in the group of liver transplant recipients treated with tacrolimus had a lower incidence of skin cancer than in the cyclosporine group. However, Jonas et al. 13 found no difference between patients receiving cyclosporine and those receiving tacrolimus. In this study population, those who did not use tacrolimus in the first year after transplantation had a statistically significant chance of developing skin cancer (p=0.0256) compared with those using this immunosuppressant.
Some studies have associated the increased incidence of post-transplant diabetes mellitus to the use of tacrolimus. 15, 16 Among the 16 patients studied that presented skin cancer, 25% (4/16) developed diabetes in the third year; of these, three received tacrolimus.
Presence of diabetes in 12.4% (21/170) of patients in the third year after the operation was also considered a risk factor (p=0.0475) for skin cancer.
In some studies, increasing age was considered a risk factor for skin cancer, similar to what is observed in several neoplasms of other organs and in some studies in transplants. [12] [13] [14] According to these studies, age greater than 40 years at the time of transplantation is a risk factor for the development of skin cancer. 12 In our study population, age was not a significant factor.
Literature reports the increase in the frequency of skin cancer after kidney transplantation to smokers or history of smoking and alcohol consumption. 17 In that study, in patients who presented alcoholic cirrhosis at the time of the operation (p=0.075), those who were smokers or who had a smoking history (0.098) showed only a tendency to develop skin cancer, since the results were not significant.
As the medical records present information to obtain the MELD and BAR score and no information was found on the relation with skin cancer, it was decided to test this possibility. In this study population, there was no relation.
It is estimated that after a solid organ transplant there is a risk 3 to 4 times higher for CMM development, 10 times higher for BCC, approximately 20 times higher for Merkel cell carcinoma, 65 times higher for SCC and 84 times higher for Kaposi's sarcoma. 8, 18, 19 Relation between SCC and BCC in kidney transplant recipients is inversely related to that of the general population, which was also observed in this study. 17 Approximately 30% to 50% of patients who were treated with kidney and heart transplants and who developed SCC also developed BCC. 20 In this study, 56.2% (9/16) of the patients presented more than one lesion, and 18.7% (3/16) of the patients who developed SCC presented BCC, a result that is lower than that found in the literature for kidney and heart transplant. 20 We were surprised to find two patients with post-transplant CMM. This incidence is higher than that found in the general population, since the gross CMM incidence rates, in the state of São Paulo, estimated in 2014, were 3.97 (men) and 4.59 (women) /100000. 21 It is a neoplasia with the potential to produce metastases and, therefore, of greater impact for the immunodeficient.
Photoexposed areas of transplanted patients with cutaneous neoplasias often have actinic damage. 22 This actinic damage is translated by extensive pre-malignant lesions, such as actinic keratoses. Their presence is associated with a higher risk of non-melanoma skin cancer, as observed in our study (OR=22,300, 95% CI = 2,870-173,271, p=0.003). 23 Neoplasias tend to develop earlier and with more aggressive expression in transplanted patients than in immunocompetent individuals, which may lead to a 5% to 8% increase in transplanted patients mortality. 8 Given the significant number of skin cancers in the populations of transplanted patients, the important morbidity and mortality associated with these diagnoses should not be neglected, which imposes their consideration as a public health problem, but with a feasible control by primary and secondary prevention. 24, 25 After transplantation, the liver receptor should be accompanied by a multidisciplinary team and undergo evaluation by a dermatologist to recapitulate the actions for the early diagnosis, prevention and treatment of skin cancer. 26 An important limitation of this study is that the interpretations of the results were based on information collected in patients undergoing transplantation in the same center. Future research, multicenter, both prospective and retrospective, are needed, involving larger and more diverse populations. Despite the methodological limitations of this type of study, these results point to the need to educate both patients and health professionals about skin cancer.
Risk factors found in this study may contribute to better monitoring in Brazilian surveillance programs and to the development of strategies associated with the reduction of the incidence of skin cancer in liver transplant patients.
CONCLUSION
Knowledge of the risk factors found in this study (diabetes in the third year after transplantation, not using tacrolimus in the first year after transplantation and actinic keratosis) may contribute to the development of specific strategies in Brazilian programs for the sur- 
